286 related articles for article (PubMed ID: 30485824)
21. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
[TBL] [Abstract][Full Text] [Related]
22. Epigenetics in ovarian cancer.
Seeber LM; van Diest PJ
Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
[TBL] [Abstract][Full Text] [Related]
23. A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.
Guerrero K; Wang Z; Bachvarova M; Gregoire J; Renaud MC; Plante M; Bachvarov D
Gynecol Oncol; 2012 Jun; 125(3):720-6. PubMed ID: 22446619
[TBL] [Abstract][Full Text] [Related]
24. Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.
Cai LY; Abe M; Izumi S; Imura M; Yasugi T; Ushijima T
Life Sci; 2007 Mar; 80(16):1458-65. PubMed ID: 17303177
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
Singh AK; Chandra N; Bapat SA
Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
[TBL] [Abstract][Full Text] [Related]
26. Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance.
Stein-O'Brien G; Kagohara LT; Li S; Thakar M; Ranaweera R; Ozawa H; Cheng H; Considine M; Schmitz S; Favorov AV; Danilova LV; Califano JA; Izumchenko E; Gaykalova DA; Chung CH; Fertig EJ
Genome Med; 2018 May; 10(1):37. PubMed ID: 29792227
[TBL] [Abstract][Full Text] [Related]
27. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.
Yang H; Das P; Yu Y; Mao W; Wang Y; Baggerly K; Wang Y; Marquez RT; Bedi A; Liu J; Fishman D; Lu Z; Bast RC
Oncotarget; 2016 Jan; 7(3):3018-32. PubMed ID: 26689988
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic silencing of ARNTL, a circadian gene and potential tumor suppressor in ovarian cancer.
Yeh CM; Shay J; Zeng TC; Chou JL; Huang TH; Lai HC; Chan MW
Int J Oncol; 2014 Nov; 45(5):2101-7. PubMed ID: 25175925
[TBL] [Abstract][Full Text] [Related]
29. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H
EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650
[TBL] [Abstract][Full Text] [Related]
30. Using epigenomics data to predict gene expression in lung cancer.
Li J; Ching T; Huang S; Garmire LX
BMC Bioinformatics; 2015; 16 Suppl 5(Suppl 5):S10. PubMed ID: 25861082
[TBL] [Abstract][Full Text] [Related]
31. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
32. Synaptotagmin-like protein 2 gene promotes the metastatic potential in ovarian cancer.
Sung HY; Han J; Ju W; Ahn JH
Oncol Rep; 2016 Jul; 36(1):535-41. PubMed ID: 27220283
[TBL] [Abstract][Full Text] [Related]
33. Both hypomethylation and hypermethylation in a 0.2-kb region of a DNA repeat in cancer.
Nishiyama R; Qi L; Lacey M; Ehrlich M
Mol Cancer Res; 2005 Nov; 3(11):617-26. PubMed ID: 16317087
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
35. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
36. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
37. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
38. Heterogeneous DNA methylation status in same-cell subpopulations of ovarian cancer tissues.
Li Q; Xue X; Li W; Wang Q; Han L; Brunson T; Xu W; Chambers-Harris I; Wang Q; Li X; Ma L; Song Q
Tumour Biol; 2017 Jun; 39(6):1010428317701650. PubMed ID: 28618935
[TBL] [Abstract][Full Text] [Related]
39. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
[TBL] [Abstract][Full Text] [Related]
40. Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data.
Kok-Sin T; Mokhtar NM; Ali Hassan NZ; Sagap I; Mohamed Rose I; Harun R; Jamal R
Oncol Rep; 2015 Jul; 34(1):22-32. PubMed ID: 25997610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
